What the studies show
Triptodur is approved for central precocious puberty in children aged two and above, as a single depot injection repeated every 24 weeks — the same axis shutdown used to halt premature puberty.
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Triptodur (triptorelin) prescribing information.DailyMed, read 29 Oct 2026Central precocious puberty in children aged 2 and above; 24-week depot.
In context
Triptorelin is a synthetic ten-amino-acid analogue of gonadotropin-releasing hormone, approved since the 1980s and sold as Trelstar for advanced prostate cancer and Triptodur for central precocious puberty. Given continuously it shuts the reproductive axis down after an initial surge. Its grey-market reputation is the opposite use — a single low dose to restart testosterone production after anabolic steroids — and that rests on one published case report of one man, not on any trial.
Triptorelin is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Triptorelin proven to help with central precocious puberty?
What studies are behind the grade?
Is Triptorelin approved for this?
Other outcomes for Triptorelin
- ATestosterone suppression in advanced prostate cancerApproval programme; decades of use
- DRestarting testosterone after anabolic steroids1 case report (n=1)
- AInitial testosterone surge ("flare")adverseApproval programme
Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →